6 completed, 5 not yet recruiting, 5 recruiting, 4 unknown. 8 Phase 3, 7 Phase 4, 2 Not applicable, 2 Phase 2, 1 Phase 1.
Follow 3-n-butylphthalide: new trials by email Literature Review of 3-n-butylphthalide trials Research Report on 3-n-butylphthalide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy 3-N-butylphthalide - Multiple System Atrophy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 150 | 2026-08-27 | 2026-10-16 |
| Butylphthalide for Brain Edema After Endovascular Treatment Butylphthalide, Placebo - Acute Ischemic Stroke | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 100 | 2026-04-01 | 2026-04-14 |
| Butylphthalide for Long-term Efficacy in Minor Stroke Study Butylphthalide, Placebo - Ischemic Stroke, Minor Stroke | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 1200 | 2025-12-01 | 2025-11-17 |
| Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT) Isosorbide Mononitrate, Butylphthalide, Isosorbide Mononitrate Placebo - Stroke, Lacunar, Stroke, Acute Ischemic | Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 3156 | 2025-12-01 | 2025-11-26 |
| Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy Butylphthalide, Placebo - Focal Epilepsy, Cognitive Impairment | Phase 4 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 220 | 2025-09-01 | 2025-09-25 |
| A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI Butylphthalide, Butylphthalide placebo - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 3 | Not yet recruiting | Xiangya Hospital of Central South University | 40 | 2024-12-01 | 2024-11-26 |
| Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment DL-3-n-butylphthalide, Empty Medication Capsules - Chemotherapy-Related Cognitive Impairment, DL-3-n-butylphthalide | Phase 4 | Not yet recruiting | First Hospital of China Medical University | 100 | 2024-07-01 | 2024-07-18 |
| Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) dl-3-butylphthalide, dl-3-butylphthalide placebo - Stroke, Post-stroke Cognitive Impairment (PSCI) | Phase 3 | Recruiting | Fudan University | 3200 | 2024-04-01 | 2024-04-15 |
| Efficacy of Butylphthalide on Symptomatic Atherosclerotic Stenosis in Middle Cerebral Artery Butylphthalide, Placebo - Ischemic Stroke, Acute, Intracranial Atherosclerosis | Not applicable | Unknown | First Affiliated Hospital, Sun Yat-Sen University | 140 | 2024-03-15 | 2024-03-26 |
| Using Real-world Evidence to Analyze the Clinical Effects and Adverse Events of Butylphthalide in Stroke Patients butylphthalide - Stroke, Cerebral Infarction | Completed | Xin Huang | 81292 | 2022-05-07 | 2024-04-09 | |
| For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide. Butylphthalide - Stroke, Cerebral Infarction | Phase 4 | Unknown | Qianfoshan Hospital | 300 | 2022-05-07 | 2024-04-09 |
| Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients Butylphthalide and Sodium Chloride Injection, Saline Solution - Butylphthalide, Cardiac Arrest | Phase 4 | Recruiting | Tang Ziren | 350 | 2022-01-01 | 2025-04-11 |
| Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) Butylphthalide and Sodium Chloride Injection, Saline Solution - Butylphthalide, Cardiac Arrest | Phase 4 | Recruiting | Tang Ziren | 100 | 2021-09-01 | 2025-02-07 |
| NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events dl-3-n-butylphthalide (NBP), Normal Saline 0.9% Infusion Solution - Moyamoya Disease, Ischemic Cerebral Infarction | Phase 3 | Unknown | yuanli Zhao | 450 | 2020-01-01 | 2019-12-19 |
| Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment Butylphthalide, Butylphthalide Placebo - Acute Ischemic Stroke | Phase 3 | Completed | Beijing Tiantan Hospital | 1216 | 2018-07-01 | 2022-08-05 |
| Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke. butylphthalide(NBP), placebo - Acute Ischemic Stroke | Phase 4 | Completed | Yi Yang | 99 | 2018-02-28 | 2022-06-30 |
| The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia NBP, Placebos - Subcortical Vascular Dementia, Cerebral Small Vessel Diseases | Not applicable | Unknown | Tianjin Medical University General Hospital | 64 | 2017-11-18 | 2019-04-08 |
| DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil DL-3-n-butylphthalide, Donepezil - Alzheimer's Disease | Completed | First Affiliated Hospital Xi'an Jiaotong University | 92 | 2016-03-01 | 2020-02-12 | |
| Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting Butylphthalide, Placebo - Restenosis | Phase 3 | Completed | Jinling Hospital, China | 100 | 2011-07-01 | 2015-10-26 |
| Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke Dl-3-n-butylphthalide, Cerebrolysin, Placebo - Acute Cerebral Stroke Within 12 Hours for the First Time | Phase 1 / Phase 2 | Completed | Shanghai 6th People's Hospital | 84 | 2010-01-01 | 2020-08-24 |
Ischemic Stroke (10) · Stroke (4) · Brain Infarction (2) · Brain Ischemia (2) · Central Nervous System Diseases (2) · Cerebral Infarction (2) · Cerebral Small Vessel Diseases (2) · Heart Arrest (2) · Nervous System Diseases (2) · Vascular Diseases (2) · Alzheimer Disease (1) · Brain Edema (1) · Cardiovascular Diseases (1) · Chemotherapy-Related Cognitive Impairment (1) · Cognitive Dysfunction (1)
Beijing Tiantan Hospital (2) · Tang Ziren (2) · First Affiliated Hospital Xi'an Jiaotong University (1) · First Affiliated Hospital of Wenzhou Medical University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · First Hospital of China Medical University (1) · Fudan University (1) · Jinling Hospital, China (1) · Nanfang Hospital, Southern Medical University (1) · Peking Union Medical College Hospital (1) · Qianfoshan Hospital (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai 6th People's Hospital (1) · Tianjin Medical University General Hospital (1) · Xiangya Hospital of Central South University (1)
China (16)
Xin Huang (2) · Huiqin Xu, MD (1) · Jiali Pu, MD (1) · Jinsheng Zeng (1) · Lixia Xue, M.D., Ph.D. (1) · Nan Zhang, MD, PhD (1) · Xinfeng Liu, MD (1) · Yi Yang, MD, PhD (1) · Yilong Wang (1) · Yuanli Zhao, MD (1)
PMID 27168844, PMID 29766771, PMID 34035100, PMID 34630292, PMID 37021629, PMID 37358859, PMID 42329209